Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC Congress 2024 Reveals its Late-Breaking Scientific Sessions
Added: 1 year ago Source:  ESC Congress
The European Society of Cardiology has revealed the late-breaking science sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30th August to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View… View more

Heart Failure

Electrophysiology & Arrhythmia
VICTOR Trial: Vericiguat Shows No Benefit for Primary Endpoint in Stable HFrEF
Added: 7 months ago Source:  Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide… View more

Guidelines & Statements

Heart Failure
Beta-Blockers Show No Benefit Post-MI in Normal LVEF
Added: 5 months ago Source:  Radcliffe Cardiology
A large-scale meta-analysis of individual patient data has found that beta-blocker therapy does not reduce the risk of major adverse cardiovascular events in patients with a preserved left ventricular ejection fraction (LVEF) following a myocardial infarction (MI).¹ The findings, from the Beta-Blocker Trialists’ Collaboration Study Group, question the routine use of this drug class in this… View more

MI/ACS

Prevention & Chronic Conditions
February’s Top 10 Cardiology Resources: Videos and Essential Reads
Added: 1 month ago Source:  Radcliffe Cardiology
Explore free-to-access cardiology content, including expert video discussions, guideline-relevant analysis and peer-reviewed reviews designed for application in cardiovascular practice.New Horizons in Dyslipidaemia 2026On-Demand Video EventWith forthcoming updates anticipated at American College of Cardiology Annual Scientific Session, dyslipidaemia management is entering a period of refinement,… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Beta-Blockers Cut MACE Risk Post-MI in Normal EF Patients
Added: 4 months ago Source:  Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open… View more

MI/ACS

Prevention & Chronic Conditions
High-Dose Flu Vaccine Linked to Reduced Cardiovascular Hospitalisations in Older Adults
Added: 7 months ago Source:  Radcliffe Cardiology
A prespecified secondary analysis of the DANFLU-2 trial suggests that a high-dose inactivated influenza vaccine (HD-IIV) may offer greater protection against cardiovascular-related hospitalisations in older adults compared to a standard-dose vaccine (SD-IIV).¹˒² While the trial’s primary endpoint was not met, these exploratory findings point to a potential benefit in reducing the burden of… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
REBOOT-CNIC: Beta-Blockers Show No Benefit Post-MI in Patients with Preserved Ejection Fraction
Added: 7 months ago Source:  Radcliffe Cardiology
The long-standing practice of prescribing beta-blockers after a myocardial infarction (MI) has been re-examined in the contemporary era of reperfusion therapy. New findings from the REBOOT-CNIC trial suggest that for patients with a preserved left ventricular ejection fraction (LVEF), this routine therapy may not provide the expected benefits.¹REBOOT-CNIC was an open-label, randomised trial… View more

Imaging & Diagnostics

MI/ACS
AI Tool Accurately Detects Cardiac Amyloidosis on Echo
Added: 5 months ago Source:  Radcliffe Cardiology
Differentiating cardiac amyloidosis (CA) from its phenotypic mimics remains a clinical challenge. A new study published in the European Heart Journal details the development and validation of a novel artificial intelligence (AI) model that can accurately screen for CA using only a single apical four-chamber echocardiogram video clip.¹This retrospective, multisite, multiethnic study first trained… View more

Imaging & Diagnostics

Demographic
FIRE Trial: Sustained Benefit of Complete Revascularization in Older MI Patients at 3 Years
Added: 6 months ago Source:  Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time… View more

Intervention

MI/ACS
POTCAST: Raising Potassium Levels Reduces Arrhythmia Risk in ICD Patients
Added: 6 months ago Source:  Arrhythmia Academy
A strategy of actively increasing plasma potassium to high-normal levels significantly lowered the risk of arrhythmia events in high-risk patients with an implantable cardioverter–defibrillator (ICD), according to results from the POTCAST trial.¹˒² The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England Journal of… View more

Electrophysiology & Arrhythmia

Heart Failure